Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

340B 'Penny Pricing' Policy Draws Manufacturers' Ire

This article was originally published in The Pink Sheet Daily

Executive Summary

Manufacturers pinpoint flaws in and outline alternatives to HRSA's plan to codify the now non-binding policy of charging a penny per pill for certain products. Concerns are raised about stockpiling and drug diversion, in addition to fair payment.

Advertisement

Related Content

A Penny Saved: Why Delaying 340B Pricing Rule Is Good News For Companies Like Horizon
340B Manufacturer Fines Outlined In Rule, But HRSA Expects To Use Them ‘Very Rarely’

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078839

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel